UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

SCHEDULE 14A

PROXY STATEMENT
PURSUANT TO SECTION 14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934

Filed by the Registrant ⊠ File		Filed by a Party other than the Registrant \square
Check the appropriate box:		
	Preliminary Proxy Statement	
	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))	
	Definitive Proxy Statement	
\boxtimes	Definitive Additional Materials	
	Soliciting Material Pursuant to Section 240.14a-1	2
IBIO, INC.		
(Name of Registrant as Specified in Its Charter)		
	(Name of Person	(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (check the appropriate box):		
\boxtimes	No fee required.	
	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.	
(1)	Title of each class of securities to which transaction applies:	
(2)	Aggregate number of securities to which transaction applies:	
(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):	
(4)	Proposed maximum aggregate value of transaction:	
(5)	Total fee paid:	
	Fee paid previously with preliminary materials.	
	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.	
(1)	Amount Previously Paid:	
(2)	Form, Schedule or Registration Statement No.:	
(3)	Filing Party:	
(4)	Date Filed:	
	-	

Explanatory Note

Commencing November 30, 2021, iBio, Inc. ("iBio") will begin posting the communication set forth below (the "Communication") on Facebook, Twitter, LinkedIn and other social media and internet platforms. The Communication supplements the Definitive Proxy Statement filed by iBio with the U.S. Securities and Exchange Commission (the "SEC") on October 26, 2021 and the Definitive Additional Materials filed by iBio with the SEC on October 26, 2021, November 9, 2021, November 16, 2021, November 17, 2021, November 24, 2021 and on the date hereof.

"...[T]he two leading independent proxy advisory firms have now affirmed our BoD's recommendation that voting FOR on all six of the proposals at our upcoming Annual Meeting will be in the best interest of our shareholders." - Tom Isett, CEO https://bit.ly/3GhMrVp \$IBIO.

Leading independent Proxy Advisory
Firm ISS Joins Glass Lewis in
Recommending That iBio Shareholders
Vote "FOR" All Proposals at iBio's
Upcoming Annual Meeting



NYSE: IBIO